Linda Grais Sells 841 Shares of Icon (NASDAQ:ICLR) Stock

Icon Plc (NASDAQ:ICLR) Director Linda Grais sold 841 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $138,167.89. Following the transaction, the director owned 6,162 shares in the company, valued at $1,012,354.98. This represents a 12.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Performance

Shares of ICLR opened at $167.48 on Friday. The company has a 50-day simple moving average of $162.22 and a two-hundred day simple moving average of $134.04. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. The firm has a market capitalization of $12.82 billion, a PE ratio of 39.31, a price-to-earnings-growth ratio of 6.93 and a beta of 1.21. Icon Plc has a one year low of $66.57 and a one year high of $203.91.

Icon (NASDAQ:ICLR) last posted its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. The firm had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.26 EPS. On average, analysts anticipate that Icon Plc will post 9.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. EFG International AG bought a new position in shares of Icon during the fourth quarter valued at $27,000. Abound Financial LLC purchased a new position in Icon in the 4th quarter worth about $54,000. GAMMA Investing LLC raised its position in Icon by 21.4% in the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after buying an additional 69 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Icon during the 3rd quarter valued at about $71,000. Finally, Blue Trust Inc. grew its stake in shares of Icon by 207.5% in the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after acquiring an additional 444 shares during the period. Institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Robert W. Baird set a $194.00 target price on shares of Icon in a report on Friday, July 31st. UBS Group set a $160.00 price target on shares of Icon in a research report on Wednesday, June 24th. Leerink Partners set a $145.00 price objective on shares of Icon in a report on Thursday, May 28th. Royal Bank Of Canada raised Icon from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $126.00 to $185.00 in a research report on Thursday, June 25th. Finally, Citigroup upped their price target on Icon from $165.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $170.40.

Key Headlines Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue of $2.06 billion topped estimates of $2.00 billion. Revenue also rose 2.3% year over year, indicating continued demand for its outsourced clinical-research services.
• Positive Sentiment: Analyst support remains a potential catalyst. BMO Capital Markets raised its price target to $187, Mizuho lifted its target to $190, and William Blair upgraded the stock to “strong buy.” The broader analyst consensus is “Hold,” with an average target of $170.40. Analyst coverage article
• Positive Sentiment: Institutional ownership is high at 95.61%, and several investment firms recently initiated or increased positions in ICLR. The stock is also trading above its 50-day and 200-day moving averages, reflecting favorable recent momentum.
• Neutral Sentiment: CEO Barry Balfe, CFO Nigel Clerkin and several directors sold shares totaling roughly $1.6 million at prices near $164.07–$164.29. The filings state that the sales were made to cover tax-withholding obligations connected with vested equity awards, and the insiders retained shares afterward, reducing the negative signal. Icon insider sales article
• Negative Sentiment: Although revenue beat estimates, quarterly EPS fell from $3.26 in the prior-year period, highlighting earnings pressure. ICLR also trades at a relatively demanding valuation, with a price-to-earnings ratio near 39 and a PEG ratio above 6, leaving the stock vulnerable if growth or guidance weakens.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.